Introduction {#sec1_1}
============

As its name implies, neuroendocrine cells are nerve-like cells disseminated widely throughout the body that release neurotransmitters and hormones including gastrin, cholecystokinin, vasoactive intestinal polypeptide, substance P and serotonin into the circulation \[[@B1]\]. These cells may undergo malignant transformation to give rise to neuroendocrine neoplasms or carcinoid tumors that, not surprisingly, given the ubiquity of neuroendocrine cells in normal tissues, arise in multiple locations, including the gastrointestinal and the genitourinary tracts as well as the lungs, where they account for up to 25% of all invasive lung malignancies \[[@B2]\].

Neuroendocrine tumors (NET) are characterized as functional or nonfunctional, depending on whether they secrete hormones, which in turn may result in specific symptoms and signs \[[@B3]\]. Carcinoid syndrome refers to variable and episodic symptoms of flushing, secretory diarrhea, tachycardia or hypotension, bronchospasm, and valvular heart disease due to the overproduction and release of substances, including serotonin, histamine, prostaglandins, kallikrein, bradykinins, substance P, gastrin, corticotrophin, and neuron-specific enolase \[[@B4]\].

RRx-001 is an aerospace-derived, systemically nontoxic anticancer agent \[[@B5]\] with radio-, chemo- and immunosensitizing properties \[[@B6]\] under active investigation in multiple tumor types including brain, colorectal, cholangiocarcinoma and lung. In the TRIPLE THREAT clinical trial (NCT02489903), so named because patients with non-small cell lung cancer, small cell lung cancer and neuroendocrine tumors (NET) are eligible, treatment consists of weekly RRx-001 administered intravenously over about 1 h until RECIST v.1.1 progression followed by retreatment with formerly effective but now refractory platinum doublets. The premise is that RRx-001, as an epigenetic inhibitor of DNA methylation and deacetylation, effects changes in gene expression that will render refractory tumors sensitive to rechallenge with formerly tried chemotherapies \[[@B7]\]. The trial has a 3-stage design for early stopping of any of the three arms in case of lack of efficacy (fig. [1](#F1){ref-type="fig"}).

Case Presentation {#sec1_2}
=================

The patient presented here is, a *RET*-mutation-positive (M918T), 64-year-old male with intermediate grade, extensive stage IV (T1N3M1a) pulmonary neuroendocrine carcinoma diagnosed on November 21, 2014, who participates in the TRIPLE THREAT trial. Starting on December 22, 2014, he received cisplatin/etoposide but discontinued on February 26, 2015, after 4 cycles for increasing complaints of nausea, decreased energy, and anorexia. On May 18, 2015, the patient was started on monthly 30-mg octreotide injections to control neuroendocrine symptoms of flushing and grade 3 diarrhea, consisting of up to 12-14 watery stools per day. On long-acting octreotide, the patient reported a reduction in his bowel movements to approximately 7 per day, but they remained loose and watery. On June 24, 2015, CT scans demonstrated progression with a new right ocular choroidal metastasis.

The patient began his first weekly infusion of RRx-001 on July 9, 2015, administered concurrently with radiation treatment to his right eye from July 14, 2015, to December 8, 2015. The octreotide was stopped when RRx-001 was started. On December 8, 2015, approximately 1 month after treatment with RRx-001 was initiated, a CT scan was performed, indicating stable disease with marked central cavitation in several tumors. A confirmatory positron emission tomography (PET)-CT scan demonstrated decreased standard uptake values, a semiquantitative measurement of the ^18^-F-fluorodesoxyglucose uptake on PET, in the majority of lesions (fig. [2](#F2){ref-type="fig"}). At the same time, since starting RRx-001, both his flushing and high-output diarrhea have significantly improved, with a reduction in the number of stools per day from 12 to 2 and increased stool consistency despite the cessation of octreotide and no use of any antidiarrheal medications (fig. [3](#F3){ref-type="fig"}). Urinary 5-HIAA levels have been measured prior to starting any treatment and were found not to be elevated.

Discussion {#sec1_3}
==========

The therapeutic options for refractory carcinoid syndrome are limited. The synthetic somatostatin analogues octreotide and lanreotide, and to a lesser extent interferon-alpha, are the mainstays of treatment \[[@B8]\]. In the literature, vascular endothelial growth factor inhibitors such as bevacizumab, tyrosine kinase inhibitors such as sunitinib and sorafenib, which also block vascular endothelial growth factor, the antivascular agent thalidomide, and the mammalian target of rapamycin inhibitors such as everolimus have been associated with an improvement in the signs and symptoms of malignant carcinoid syndrome \[[@B3]\].

To our knowledge, this is the first report of a hormone syndrome control with an epigenetic agent in a functioning NET with a typical carcinoid syndrome. The mechanism by which RRx-001 may inhibit hormone release is unclear. It is possible that the epigenetic modification of gene transcription may have led to a reduction in the transcription and subsequent production of bioactive mediators such as serotonin. Alternatively, the antivascular properties of RRx-001 \[[@B9]\], well documented in preclinical experiments \[[@B10]\], may have contributed. In addition, RRx-001-induced tumor necrosis and a decrease in the number of hormone-secreting cells may have been at least partly responsible.

From this N-of-1 study, it is manifestly impossible to draw significant conclusions about the efficacy of epigenetic agents in general, and RRx-001, in particular, in NET; however, the rapid reversal of symptoms and improved quality of life for this patient necessitates further investigation in the TRIPLE THREAT trial. These clear clinical benefits also possibly suggest that a trial of approved low-dose epigenetic agents such as 5-azacitidine or vorinostat in the context of refractory carcinoid syndrome, when all other agents have failed, may be warranted.
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![**a** Baseline PET-CT scan showing a right anterior mediastinal metastasis. **b** PET-CT scan of the same region after 8 weeks of therapy with RRx-001 showing partial regression in size and decreased standard uptake values, denoting a metabolic response.](cro-0008-0461-g02){#F2}
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